Stockreport

Immunic Inc (IMUX) Reports Year-End 2023 Financial Results [Yahoo! Finance]

Immunic, Inc.  (IMUX) 
PDF Clinical Developments : Positive interim analysis from Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis. Patent Portfolio Expansion : [Read more]